Cargando…

Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells

Detalles Bibliográficos
Autores principales:	Norris, E J, DeStephanis, D, Tunquist, B, Usmani, S, Ganapathi, R, Ganapathi, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098264/ https://www.ncbi.nlm.nih.gov/pubmed/27716742 http://dx.doi.org/10.1038/bcj.2016.92

Ejemplares similares

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2019)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
por: Roy, V, et al.
Publicado: (2015)

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)
por: Maruyama, Dai, et al.
Publicado: (2022)

Therapy-related acute promyelocytic leukemia in plasma cell myeloma treated with melphalan: a case report and literature review
por: Gu, Hyunjung, et al.
Publicado: (2017)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Musculoskeletal chronic graft versus host disease – A rare complication of allogeneic hematopoietic stem cell transplantation: A case report and review of its literature
por: Goli, Vasu Babu, et al.
Publicado: (2017)

Reply to Letter to Editor: Femoral Component Positioning in Hip Resurfacing with and Without Navigation
por: Vendittoli, Pascal-André, et al.
Publicado: (2009)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Transcriptomic changes in single yeast cells under various stress conditions
por: Su, Yangqi, et al.
Publicado: (2023)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1
por: Norris, Eric J., et al.
Publicado: (2018)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study
por: Dhakal, Binod, et al.
Publicado: (2023)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Immune Cell and Adipose Gene Expression Reprogramming in Juvenile Monkeys Born to Health and Weight-Diverse Mothers
por: Ruggiero, Alistaire, et al.
Publicado: (2021)

Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells
por: Xiong, Ting, et al.
Publicado: (2015)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

Austrian Syndrome and Multiple Myeloma: A Fatal Combination
por: Baig, Abdur, et al.
Publicado: (2012)

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma
por: Lee, Seung-Shin, et al.
Publicado: (2019)

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
por: Byrgazov, Konstantin, et al.
Publicado: (2020)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
por: Heuck, C J, et al.
Publicado: (2014)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.
por: Robinson, B. A., et al.
Publicado: (1985)

Cannot write session to /tmp/vufind_sessions/sess_pska6unn17s37t39gspk9uv718